Literature DB >> 6097034

Characterisation and physical mapping of an HSV-1 glycoprotein of approximately 115 X 10(3) molecular weight.

E A Buckmaster, U Gompels, A Minson.   

Abstract

A type-specific monoclonal antibody that efficiently neutralises HSV-1 immunoprecipitated a glycoprotein of slightly greater electrophoretic mobility than gB from HSV-1 infected cells. Pulse and pulse chase experiments indicate that this glycoprotein is distinct from HSV-1 glycoproteins gB, gC, gD, and gE. This was confirmed by the reactions of LP11 with a series of intertypic recombinants the results of which indicate that the LP11 target gene is located close to the HSV-1 thymidine kinase gene between map positions 0.28 and 0.31. In accordance with the presently agreed convention this glycoprotein should be designated gH-1, and it may correspond to the 110K glycoprotein described by S. D. Showalter, M. Zweig, and B. Hampar (1981), Infect. Immun. 34, 684-692. Antibody LP11 inhibits plaque formation when added to cell monolayers after infection suggesting that gH-1 may play a role in cell-to-cell spread of infectious virus.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097034     DOI: 10.1016/0042-6822(84)90387-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  73 in total

1.  Assembly and organization of glycoproteins B, C, D, and H in herpes simplex virus type 1 particles lacking individual glycoproteins: No evidence for the formation of a complex of these molecules.

Authors:  G Rodger; J Boname; S Bell; T Minson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Glycoprotein H of pseudorabies virus is essential for entry and cell-to-cell spread of the virus.

Authors:  B Peeters; N de Wind; R Broer; A Gielkens; R Moormann
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Glycoprotein gI of pseudorabies virus promotes cell fusion and virus spread via direct cell-to-cell transmission.

Authors:  L Zsak; F Zuckermann; N Sugg; T Ben-Porat
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Oligomer formation of the gB glycoprotein of herpes simplex virus type 1.

Authors:  S L Highlander; W F Goins; S Person; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Live visualization of herpes simplex virus type 1 compartment dynamics.

Authors:  Anna Paula de Oliveira; Daniel L Glauser; Andrea S Laimbacher; Regina Strasser; Elisabeth M Schraner; Peter Wild; Urs Ziegler; Xandra O Breakefield; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

6.  Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production.

Authors:  S D Marlin; S L Highlander; T C Holland; M Levine; J C Glorioso
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

7.  The UL10 gene of herpes simplex virus 1 encodes a novel viral glycoprotein, gM, which is present in the virion and in the plasma membrane of infected cells.

Authors:  J D Baines; B Roizman
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry.

Authors:  C Krummenacher; A V Nicola; J C Whitbeck; H Lou; W Hou; J D Lambris; R J Geraghty; P G Spear; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Differential rates of processing and transport of herpes simplex virus type 1 glycoproteins gB and gC.

Authors:  M Sommer; R J Courtney
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complex.

Authors:  T Peng; M Ponce de Leon; M J Novotny; H Jiang; J D Lambris; G Dubin; P G Spear; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.